An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.
An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
Inclusion criteria:
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Washington D.C., District of Columbia 20007-2113, United States
Brasilia-DF, Brazil
Curitaba, Brazil
Porto Alegre-RS, Brazil
Plzen-Lochotin, Czechia
Pokfulam, Hong Kong
San Giovanni Rotundo, Italy
Tarante, Italy
Via Pansini, Italy
Georgetown, Penang, Malaysia
Subang Jaya, Selangor, Malaysia
Deajeon, South Korea
Jeollanam-do, South Korea
Cataluna, Spain
San Sabastian, Pais Vasco, Spain